国产胸腺肽α1对恶性肿瘤化疗患者免疫功能的影响

Immunomodulatory effects of thymosin α1 on cancer patients during chemotherapy

目的观察胸腺肽α1对恶性肿瘤患者细胞免疫功能的影响。方法50例恶性肿瘤患者随机分为两组,实验组化疗期间同时予胸腺肽α1 1.6 mg/次,皮下注射,每周2次,连续应用8周;对照组采用单一化疗。两组病例在治疗前后分别检测T淋巴细胞亚群及NK淋巴细胞活性。结果实验组CD4、CD4/CD8、NK淋巴细胞治疗后明显高于治疗前,差异有显著性(P<0.05)。对照组治疗前后各项免疫指标差异无显著性。结论国产胸腺肽α1可提高恶性肿瘤化疗患者的细胞免疫功能,有辅助治疗的作用,且未发生明显的毒副反应,是一种低毒高效的生物免疫调节剂。

Objective To observe the immunomodulatory effects of thymosin α1 on advanced cancer patients during chemotherapy. Methods Fifty patients with advanced cancer were randomly and equally divided into two groups receiving chemotherapy or chemotherapy in combination with thymosin α1 at a twice weekly dose of 1.6 mg by subcutaneous injection for 8 weeks. The peripheral blood T cell subsets （ CIM, CIM/CD8 ）and natural killer（NK） activity of patients in both groups were measured by flow cytometry before and after treatment. Results After treatment, the blood levels of CIM, CIM/CD8 and NK cell activity in chemotherapy ＋ thymosin group were significantly higher than those before treatment （ P 〈 0.05 ）. After treatment,the NK cell activity in chemotherapy ＋ thymosin group was significantly higher than that in control group（P 〈 0.05 ）. Conclusion The immunological function of cancer patients is significantly elevated by thymosin α1 treatment and no obvious side effects were observed.